Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.66
(3.29%)
INR 16.66
(3.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 253.14 Million INR | 26.13% |
| 2022 | 200.7 Million INR | 1.42% |
| 2021 | 197.9 Million INR | -32.16% |
| 2020 | 291.72 Million INR | 104.67% |
| 2019 | 142.53 Million INR | 28.52% |
| 2018 | 110.9 Million INR | 28.25% |
| 2017 | 86.47 Million INR | -18.82% |
| 2016 | 106.51 Million INR | 2.86% |
| 2015 | 103.55 Million INR | 6.14% |
| 2014 | 97.56 Million INR | 4.72% |
| 2013 | 93.16 Million INR | 64.72% |
| 2012 | 56.55 Million INR | 61.34% |
| 2011 | 35.05 Million INR | 1617.18% |
| 2010 | 2.04 Million INR | -95.37% |
| 2009 | 44.13 Million INR | 66.93% |
| 2008 | 26.43 Million INR | -26.27% |
| 2007 | 35.85 Million INR | -12.06% |
| 2006 | 40.77 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 76.32 Million INR | 3.08% |
| 2023 Q4 | 74.04 Million INR | 5.75% |
| 2023 Q3 | 70.01 Million INR | 7.52% |
| 2023 Q2 | 65.11 Million INR | 48.12% |
| 2023 Q1 | 43.96 Million INR | -48.12% |
| 2023 FY | 253.14 Million INR | 26.13% |
| 2022 Q1 | 38.67 Million INR | -18.71% |
| 2022 FY | 200.7 Million INR | 1.42% |
| 2022 Q4 | 84.73 Million INR | 104.43% |
| 2022 Q3 | 41.44 Million INR | 15.41% |
| 2022 Q2 | 35.91 Million INR | -7.14% |
| 2021 Q4 | 47.57 Million INR | 18.55% |
| 2021 Q2 | 56.21 Million INR | 4.15% |
| 2021 Q3 | 40.13 Million INR | -28.62% |
| 2021 FY | 197.9 Million INR | -32.16% |
| 2021 Q1 | 53.97 Million INR | -22.33% |
| 2020 Q3 | 100.22 Million INR | 8.53% |
| 2020 Q4 | 69.48 Million INR | -30.67% |
| 2020 FY | 291.72 Million INR | 104.67% |
| 2020 Q1 | 29.65 Million INR | -15.42% |
| 2020 Q2 | 92.35 Million INR | 211.42% |
| 2019 Q4 | 35.06 Million INR | 0.15% |
| 2019 Q1 | 29.69 Million INR | 34.79% |
| 2019 Q2 | 42.77 Million INR | 44.08% |
| 2019 Q3 | 35 Million INR | -18.16% |
| 2019 FY | 142.53 Million INR | 28.52% |
| 2018 Q1 | 20.5 Million INR | 18.63% |
| 2018 FY | 110.9 Million INR | 28.25% |
| 2018 Q4 | 22.02 Million INR | -42.28% |
| 2018 Q3 | 38.16 Million INR | 26.34% |
| 2018 Q2 | 30.2 Million INR | 47.28% |
| 2017 Q2 | 20.06 Million INR | -0.89% |
| 2017 FY | 86.47 Million INR | -18.82% |
| 2017 Q4 | 17.28 Million INR | -40.12% |
| 2017 Q3 | 28.87 Million INR | 43.89% |
| 2017 Q1 | 20.24 Million INR | -13.73% |
| 2016 Q1 | 25.29 Million INR | 12.35% |
| 2016 FY | 106.51 Million INR | 2.86% |
| 2016 Q4 | 23.46 Million INR | 0.0% |
| 2015 Q3 | 26.5 Million INR | -17.27% |
| 2015 Q1 | 22.5 Million INR | 30.54% |
| 2015 Q2 | 32.03 Million INR | 42.34% |
| 2015 FY | 103.55 Million INR | 6.14% |
| 2015 Q4 | 22.51 Million INR | -15.02% |
| 2014 Q3 | 32.74 Million INR | 5.28% |
| 2014 Q1 | 16.47 Million INR | -36.99% |
| 2014 Q2 | 31.1 Million INR | 88.75% |
| 2014 FY | 97.56 Million INR | 4.72% |
| 2014 Q4 | 17.23 Million INR | -47.35% |
| 2013 Q2 | 23.34 Million INR | 44.55% |
| 2013 Q4 | 26.14 Million INR | -4.97% |
| 2013 FY | 93.16 Million INR | 64.72% |
| 2013 Q1 | 16.15 Million INR | 49.84% |
| 2013 Q3 | 27.51 Million INR | 17.87% |
| 2012 Q4 | 10.77 Million INR | -52.21% |
| 2012 Q2 | 22.7 Million INR | 4249.81% |
| 2012 Q3 | 22.55 Million INR | -0.68% |
| 2012 Q1 | 522 Thousand INR | 0.0% |
| 2012 FY | 56.55 Million INR | 61.34% |
| 2011 FY | 35.05 Million INR | 1617.18% |
| 2010 FY | 2.04 Million INR | -95.37% |
| 2009 FY | 44.13 Million INR | 66.93% |
| 2008 FY | 26.43 Million INR | -26.27% |
| 2007 FY | 35.85 Million INR | -12.06% |
| 2006 FY | 40.77 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 95.889% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.202% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 94.624% |
| Granules India Limited | 4.05 Billion INR | 93.754% |
| Indoco Remedies Limited | 984.6 Million INR | 74.29% |
| Achyut Healthcare Limited | 5.73 Million INR | -4316.294% |
| Ajanta Pharma Limited | 8.16 Billion INR | 96.898% |
| Alkem Laboratories Limited | 17.95 Billion INR | 98.59% |
| Alpa Laboratories Limited | 167.76 Million INR | -50.891% |
| Brooks Laboratories Limited | -195.91 Million INR | 229.207% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 84.327% |
| Bajaj HealthCare Limited | -837.93 Million INR | 130.21% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 66.451% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.545% |
| Eris Lifesciences Limited | 3.91 Billion INR | 93.542% |
| FDC Limited | 3.05 Billion INR | 91.706% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 101.686% |
| Gufic Biosciences Limited | 861.35 Million INR | 70.611% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 93.987% |
| Ipca Laboratories Limited | 5.47 Billion INR | 95.375% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -12.693% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 228.313% |
| Lasa Supergenerics Limited | -217.3 Million INR | 216.491% |
| Laurus Labs Limited | 1.6 Billion INR | 84.233% |
| Lupin Limited | 19.14 Billion INR | 98.678% |
| Mankind Pharma Limited | 19.12 Billion INR | 98.677% |
| Medicamen Biotech Limited | 109.31 Million INR | -131.582% |
| Medico Remedies Limited | 82.9 Million INR | -205.325% |
| Megasoft Limited | -127.46 Million INR | 298.596% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.177% |
| Piramal Pharma Limited | 178.2 Million INR | -42.055% |
| RPG Life Sciences Limited | 876.6 Million INR | 71.122% |
| Sigachi Industries Limited | 571.8 Million INR | 55.729% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.736% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 91.57% |
| Unichem Laboratories Limited | -704.74 Million INR | 135.92% |
| Wanbury Limited | 559.56 Million INR | 54.761% |
| Windlas Biotech Limited | 581.87 Million INR | 56.495% |
| ZIM Laboratories Limited | 172.46 Million INR | -46.78% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.344% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 106.538% |
| Divi's Laboratories Limited | 16 Billion INR | 98.418% |
| Hester Biosciences Limited | 188.89 Million INR | -34.016% |
| Procter & Gamble Health Limited | 2 Billion INR | 87.405% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 43.712% |
| Bal Pharma Limited | 73.92 Million INR | -242.445% |
| Strides Pharma Science Limited | -706.14 Million INR | 135.849% |
| Venus Remedies Limited | 284.9 Million INR | 11.15% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 88.329% |
| Nectar Lifesciences Limited | 49.95 Million INR | -406.791% |
| Shilpa Medicare Limited | 318.74 Million INR | 20.581% |
| Aarti Drugs Limited | 1.71 Billion INR | 85.232% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 81.169% |
| Suven Life Sciences Limited | -1.05 Billion INR | 124.091% |
| Ind-Swift Limited | 142.31 Million INR | -77.877% |
| Valiant Laboratories Limited | 3.19 Million INR | -7820.588% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 95.419% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 104.462% |
| Themis Medicare Limited | 435.23 Million INR | 41.838% |
| Hikal Limited | 696.02 Million INR | 63.63% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.472% |
| Sequent Scientific Limited | -358.69 Million INR | 170.574% |
| Novartis India Limited | 851.9 Million INR | 70.285% |
| Wockhardt Limited | -4.63 Billion INR | 105.467% |
| Jubilant Pharmova Limited | 771 Million INR | 67.167% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -3469.402% |
| Neuland Laboratories Limited | 3 Billion INR | 91.564% |
| Morepen Laboratories Limited | 961.59 Million INR | 73.675% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -73.368% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 379.046% |